Month: September 2025
Global Consensus Recommendations for Metabolic Dysfunction Associated Steatotic Liver Disease and Steatohepatitis
This month’s cover of the prestigious journal Gastroenterology features a landmark study by the Global NASH/MASH Council (GNC), which developed global consensus recommendations on the burden, risk stratification, and treatment of MASLD/MASH. By systematically reviewing 61 guidance documents worldwide, the study identified 46 areas of discordance that may create uncertainty for clinicians. Through a four-round Delphi process, experts established unified recommendations on screening, risk stratification, and treatment, providing a practical resource to help clinicians identify high-risk patients, optimize management of comorbidities, and select preferred therapies. While these recommendations will need ongoing updates as new therapies and noninvasive tests emerge, the framework also serves to standardize global approaches to MASLD/MASH management and facilitate more consistent research and patient care.
Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health, and Personalized Care
The prevalence of MASLD/MASH is rising globally, highlighting the urgent need for public health policies that emphasize both prevention and personalized care. MASLD/MASH carries significant clinical, humanistic, and economic burdens worldwide. Primary prevention strategies should prioritize lifestyle interventions guided by a social nutrition agenda, alongside public health initiatives to increase awareness among healthcare practitioners and the general public. For secondary prevention, non-invasive tests (NITs) should be implemented in primary care to enable early disease detection, and approved, accessible therapies targeting MASH should be recommended. Addressing MASLD/MASH through this integrated approach—combining policy reform, public health action, and personalized care—is critical to mitigating its growing impact. An article by the Global NASH/MASH Council (GNC) published today in Liver International, summarizes these important issues and explores all relevant topics in detail.
Welcoming the New Co-Chairs of the Patient Advocacy Committee of GNC/GLC
The GNC and GLC extend their heartfelt appreciation to Diane Langenbacher and Nikos Dedes for their outstanding leadership as co-chairs of the Patient Advocacy Committee over the past several years. Their dedication has been instrumental in ensuring that the patient voice remains central to all our initiatives, and we are deeply grateful for their contributions. We are also pleased that both Diane and Nikos will continue to serve as valued members of the committee. We are delighted to welcome Michael Betel and Jen Jones as the new co-chairs. Michael, President and Founder of the Fatty Liver Alliance, brings more than 30 years of leadership experience and has been a driving force in raising global awareness of MASLD and MASH while advocating for research, resources, and patient care. Jen, Founder of Sober Livers, is a powerful advocate for individuals living with alcohol-associated liver disease. Through her experience and professional expertise, she has championed efforts to reduce stigma, expand peer support, and promote equitable care in both national and international forums. Together, Michael and Jen bring vision, energy, and commitment that will be invaluable as the Patient Advocacy Committee enters its next chapter, ensuring that the needs and voices of patients continue to guide the work of the GNC and GLC.
ALEH 2025 – Global NASH/MASH Council / The Global Liver Council
This year’s annual ALEH meeting in Lima, Peru features a highly scientific and exciting program. The Global NASH/MASH Council (GNC) and Global Liver Council (GLC) are proud to partner with ALEH to address key topics related to MASLD in Latin America. The GNC/GLC session is scheduled for September 30, 2025, from 15:00 to 17:30.